tirzepatide우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42492687
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
- 저자
- Serena X Gao, Tito Borner
- 저널
- Appetite
- 공개일
- 2026 Jul 23
- 연구 유형
- 기타
- DOI
- 10.1016/j.appet.2026.108723
문헌 요약
Glucagon-like peptide-1 receptor (GLP-1R) agonists have transformed obesity pharmacotherapy, producing clinically meaningful weight loss and robust improvements in glycemic control. Yet their efficacy remains constrained by dose-limiting gastrointestinal adverse effects, including nausea and vomiting, that reduce adherence and limit escalation to maximall…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.